Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001185185-26-001313
Filing Date
2026-04-09
Accepted
2026-04-09 06:04:15
Documents
12
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 20-F/A1 anbio20fa1123125.htm   iXBRL 20-F/A 49873
  Complete submission text file 0001185185-26-001313.txt   274842

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nnnn-20251231.xsd EX-101.SCH 3314
3 XBRL DEFINITION FILE nnnn-20251231_def.xml EX-101.DEF 19790
4 XBRL LABEL FILE nnnn-20251231_lab.xml EX-101.LAB 38269
5 XBRL PRESENTATION FILE nnnn-20251231_pre.xml EX-101.PRE 20180
15 EXTRACTED XBRL INSTANCE DOCUMENT anbio20fa1123125_htm.xml XML 7679
Mailing Address FRIEDRICH-EBERT-ANLAGE 49 FRANKFURT AM MAIN 2M 60308
Business Address FRIEDRICH-EBERT-ANLAGE 49 FRANKFURT AM MAIN 2M 60308 4916096247281
Anbio Biotechnology (Filer) CIK: 0001982708 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 20-F/A | Act: 34 | File No.: 001-42526 | Film No.: 26849720
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)